Specialty Council on Nuclear Pharmacy

2023 Members

Melissa Foster, PharmD, BCNP {Chair}
MFosterFoster is a nuclear pharmacy manager with Cardinal Health Nuclear & Precision Health Solutions in Chattanooga, TN, overseeing radiopharmacy operations. She is a certified Kaizen Leader and Sponsor, serves as a field member of the Pharmacy Practice Peer Review Committee and is a subject matter expert in optimizing cyclotron and pharmacy efficiencies. She has held past roles as a staff nuclear pharmacist and as a radiation safety officer. She received her B.S. in Pharmaceutical Sciences and Doctor of Pharmacy from the University of Mississippi. She enjoys sharing her knowledge and passion for nuclear pharmacy by mentoring peers, employees, and students.

Leana Gebo, PharmD, BCNP {Vice Chair}
 Gebo is the nuclear pharmacy manager for Cardinal Health Nuclear & Precision Health Solutions in Beltsville, MD overseeing operations at the 60+ employee radiopharmacy which services the Washington, DC/Baltimore, MD metro markets and beyond. During her career as a nuclear pharmacist since 2007, Gebo has served as a staff nuclear pharmacist, radiation safety officer, certified Kaizen Leader, and pharmacist in charge. She enjoys overseeing clinical trial programs for both low and high energy products, seeing novel radiopharmaceuticals come to market, and striving to provide excellent service to her customers and patients. Gebo received her PharmD from Nova Southeastern University in Fort Lauderdale, FL.

Jeff Clanton, DPh, MS, BCNP
Dr. Clanton has been a leader and supporter of the nuclear pharmacy and nuclear medicine professions for over 40 years where he had the opportunity to develop vast firsthand experience with single photon, positron emitting and therapeutic radiopharmaceuticals. Experience that includes research (INDs), regulatory (NRC, USP, cGMP and pharmacy law) as well as operations. During his 38 plus year career at Vanderbilt University Medical Center, he was Director of Radiopharmacy Services, Manager of the Cyclotron Facility and a member of the Medical School Faculty where he was responsible for production, operation and delivery of prepared radiopharmaceuticals to the patient. Additionally, his job entailed teaching, research, regulatory compliance, procurement, and budgets. Dr. Clanton co-authored and maintained three Investigational New Drug applications {INDs), authored or co-authored 90+ peer-reviewed scientific papers and 100+ abstracts for presentation at national meetings. He was a long-standing member of the Pharmacy and Therapeutics committee, Human Subjects Radiation Committee, Radiation Safety Committee, and Chairman of Radioactive Drug Research Committee. Dr. Clanton co-founded and co-owned an independent, commercial radiopharmacy and was responsible for operations and regulatory compliance. In addition, as a consultant for PETNet Pharmaceutical Services, he was responsible for the placement, build out, training, compliance and startup of three PET cyclotron manufacturing facilities with pharmacies in Kentucky, Arkansas and Louisiana He is active in the American Pharmacists Association (APhA) serving as a past national delegate (Section on Pharmacy Specialties). His service with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) included acting as President of the Radiopharmaceutical Sciences Council. He served on multiple committees within the Board of Pharmaceutical Specialties (BPS) having been in the first group of pharmacists certified in 1982 (BCNP) and on several committees for the United States Pharmacopeia (USP). He is the 2020 recipient of the William H. Briner Distinguished Achievement Award in Nuclear Pharmacy Practice to be presented at APhA’s annual meeting. He is currently an Independent Radiopharmacy Consultant, based in Nashville, Tennessee. He enjoys assisting his clients develop a better understanding regarding radiopharmaceutical sciences and compliance.

Ronald J. Crowe, RPh, BCNP
Crowe is the Managing Director of the Emory University Center for Systems Imaging Radiopharmacy Core in Atlanta, Georgia. He has been practicing Nuclear Pharmacy since graduating from the University of Georgia College of Pharmacy in 1990. Crowe obtained his BCNP designation in 1993. He has been managing the PET Radiopharmacy at Emory since 1997 and works primarily with human research PET radiopharmaceuticals under RDRC oversite but also translates new radiopharmaceuticals from “benchtop to bedside” through the submission of FDA Investigational New Drug applications.

Paul Knapp, RPh, MBA, BCNP
PKnappKnapp is a graduate of The University of Pittsburgh School of Pharmacy, and has been a nuclear pharmacist since graduating in 1995. He has been Board Certified since 1998, and earned an MBA from Franklin University in 2008. After staffing, managing, and serving as RSO at several Cardinal Health radiopharmacies, Knapp joined their Quality & Regulatory Department in 2006 where he now manages programs dealing with clinical trial services, R&D, new product launches, patient privacy, government and industry relations, and general radiopharmaceutical practice and clinical support. He is active in several professional and industry organizations, including APhA, CORAR, and BPS.

Charles E. Leonard, PharmD, MSCE
Leonard is a Research Assistant Professor of Epidemiology in the Department of Biostatistics, Epidemiology, and Informatics at the Perelman School of Medicine at the University of Pennsylvania. He earned his doctoral degree in pharmacy from Duquesne University and his master’s degree in clinical epidemiology from the University of Pennsylvania. He completed fellowships in clinical epidemiology and pharmacoepidemiology at the University of Pennsylvania. Dr. Leonard’s research interests and experience lie in the design and conduct of post-marketing drug safety studies, especially related to drug-induced sudden cardiac arrest and clinical sequelae of drug interactions.

Nic Mastascusa, PharmD, RPh, BCNP
Mastascusa is the Chief Nuclear Pharmacist at The University of Iowa Hospitals & Clinics and Clinical Assistant Professor at the University of Iowa College of Pharmacy. He earned his pharmacy degree at the University of Iowa, completed authorized nuclear pharmacist training through Purdue University in 2008 and became board certified in 2017. He oversees the daily clinical functions of the radiopharmacy and thoroughly enjoys teaching pharmacy students, radiology residents and nuclear medicine technology students. Mastascusa is active in multiple organizations including APhA and SNMMI. He has had several roles in his career including pharmacy manager, radiation safety officer and customer services and education coordinator for a commercial radiopharmacy

Steve Mattmuller, MS, RPh, BCNP
Mattmuller is the Chief Nuclear Pharmacist at Kettering Medical Center in Kettering, OH. He received his BSPh from the Ohio Northern University and his MSRPh from the University of Southern California. He currently oversees all operations involving the preparation of SPECT radiopharmaceuticals and the production of PET radiopharmaceuticals. Mattmuller has been active with APhA and the SNMMI as well as serving on the NRC ACMUI committee.

Eric Smith, PharmD, MS, BCNP, FAPhA
Smith is a Senior Expert in the Targeted Alpha Therapy team at Bayer Pharmaceuticals. He also holds an appointment as Professor of Pharmacy at University of North Carolina’s Eshelman School of Pharmacy. He received a bachelor’s degree in chemistry from Cedarville University, and then earned his master’s and Doctor of Pharmacy degrees from Purdue University.

Shunsuke Toyoda, PharmD, BCPS, BCNSP, BCSCP, CPHQ
Dr.Toyoda obtained Bachelor’s Degree in Chemistry from Occidental College, and Doctor of Pharmacy from University of California- San Francisco School of Pharmacy. Dr.Toyoda works at PIH Health Hospital-Whittier in Los Angeles, California, as a sterile compounding pharmacist. He ensures that sterile products for the hospital is compounded in accordance to USP 797 standards. As a PGY1 preceptor, he also teaches inpatient sterile compounding procedure. Dr.Toyoda volunteers his time to continuing education sessions for Japan and the US on sterile compounding topics.